Industry Explorers Blaze On

  1. Finance And Funding: Anticipating Improvement, Planning For Uncertainty 12/1/2023

    Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.

  2. Biopharma's Eminent Challenges In 2024 — Inside & Out 12/1/2023

    A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.

  3. Accelerating Drug Development With Real World Data 12/1/2023

    Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.

  4. Executive Outlook: Converting Innovative Science Into Predictable Returns 12/1/2023

    Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.

  5. Defining A Competitive Next-Gen RNA Therapeutic In 2024 12/1/2023

    To start singling-out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives.

  6. Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place 12/1/2023

    Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.

  7. Moving Beyond AAV: The Next Generation Of Vectors In CGT 12/1/2023

    We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.

  8. An Outsourcing Future Of Information Sharing And Commercial Streamlining 12/1/2023

    Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals think about the future of working with CDMOs.

  9. You Can Increase Your Odds Of Hiring And Retaining The Best Talent 12/1/2023

    Finding scientific talent is an arduous process, often stealing precious time from our calendars. Furthermore, hiring well doesn’t have to be left to chance. Try these specific actions.

  10. Top 10 Reasons For Oral Dose CMO Preference 12/1/2023

    Just under one-third of respondents who participated in ISR’s Oral Dosage Forms Market Outlook research shared that Familiarity/History of working together/Prior positive experience are the reasons behind their preferences.